An Interview With Philip Thorpe, Lead Researcher Of The Recent Bavituximab Study

On July 11, 2009, in Highly Accessed, Immunology, submitted by Christopher Fisher, PhD
green_circular_virus_interview

Dr. Philip Thorpe, Ph.D., lead researcher of the Bavituximab study [1] reviewed on this website, recently agreed to conduct an interview with The Behavioral Medicine Report. The original review of his research turned out to be a highly accessed article that justified a follow-up interview with Dr. Thorpe. I also wanted to clarify my understanding of Bavituximab and its treatment implications and to better determine if the excitement that surrounds Bavituximab is justified.

One Step Closer To Antiviral Treatments for Persons Infected With Latent Viruses

On May 21, 2009, in Highly Accessed, Immunology, submitted by Christopher Fisher, PhD
green_circular_virus

Latent viruses and their damaging effects and possible cures are an intense focus of current research efforts. I not aware of any cure for these elusive latent viruses, who are virtually undetectable by the immune system during latent stages. Examples of latent viruses include herpes, Epstein Bar, and Cytomegalovirus. Latent viruses are suspected, and occasionally proven, to be casual or contributing factors to mental/developmental disorders, such as autism and schizophrenia and to physical disorders like high blood pressure and atherosclerosis (see the first link).